SynthesisInternational urology and nephrology2025
A meta-analysis examining the impact of prostaglandins on diabetic nephropathy.
Synthesis in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2021, approximately 537 million adults globally had diabetes, with projections estimating an increase to 643 million by 2030 and 783 million by 2045. Uncontrolled diabetes can cause severe complications, including diabetic nephropathy, a prevalent microvascular disease and a primary contributor to end-stage renal failure, with an increasing mortality rate.
methodsConduct a search for randomized controlled trials (RCTs) on the use of prostaglandins in treating diabetic nephropathy across PubMed, Cochrane Library, Web of Science, CNKI, and Wanfang databases. Two researchers will independently screen the retrieved literature, assess the methodological quality using the bias risk assessment tool from the Cochrane 5.1 manual, and conduct statistical data analysis.
resultsA total of 1019 patients were included in 11 studies. The meta-analysis results show the effective rate of the test group, which was significantly higher (P < 0.01, OR 1.32; 95% CI 1.13-1.55) than the control group.24-h urinary protein quantification of the test group was lower (P < 0.01, SMD - 2.12; 95% CI - 3.26 to - 0.99). The test group exhibited significantly lower levels of blood creatinine (P < 0.01, SMD - 0.99; 95% CI - 1.42 to - 0.57) and blood urea nitrogen (P < 0.01, SMD - 0.93; 95% CI - 1.34 to - 0.51).
conclusionThe findings suggest that prostaglandins enhance the effective rate and improve 24-h urinary protein quantification, blood creatinine, and blood urea nitrogen levels in diabetic nephropathy patients.
Indexed as
Identifiers
39971865What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.